Health Canada approves fast-acting mealtime insulin, Fiasp®, for children with diabetes

Health Canada also expands Fiasp^® approval to include insulin infusion pumps

MISSISSAUGA, ON, March 9, 2020 /CNW/ – Fiasp^® (insulin aspart injection), a faster acting mealtime insulin, is now approved in Canada for pediatric patients aged 2 years and above giving Canadian families managing type 1 or type 2 diabetes an effective treatment option to support optimal mealtime glucose control.¹ Health Canada has also expanded the approval of Fiasp^® (10 mL vials) to include use in insulin infusion pumps for the improvement of glycemic control.

Diabetes is one of the most common chronic diseases among children and youth.² Managing diabetes can be challenging for parents and caregivers given it is hard to know exactly how much or how quickly their children will eat, making mealtime insulin dosing difficult.^3,4,5  Missed meals, illness and increased physical activity without a corresponding reduction in insulin or increase in carbohydrate consumption can lead to significant diabetes management complications for children.⁶

Read on –> NewsWire.ca